- Associated Press - Tuesday, October 12, 2010

NEW YORK (AP) - In a story Oct. 11, The Associated Press reported that the Food and Drug Administration denied approval to JZP-6, a Jazz Pharmaceuticals drug candidate intended to treat fibromyalgia. The drug is approved under the name Xyrem as a treatment for narcolepsy and cataplexy.

Sign up for Daily Newsletters

Manage Newsletters

Copyright © 2020 The Washington Times, LLC.

Please read our comment policy before commenting.


Click to Read More and View Comments

Click to Hide